Has Stephen Ramee, MD received payments from drug or device companies?

Yes. Drug and device makers reported $56,129 in general payments to Stephen Ramee, MD across 246 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Stephen Ramee, MD did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Stephen Ramee, MD come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Stephen Ramee, MD

Interventional Cardiology · New Orleans, LANPI 1780630038

Payments from drug & device makers

What this record shows

The money is spread across several categories — consulting fees (40.8%), food and beverage and speaking fees — rather than concentrated in one kind of arrangement. 28 manufacturers reported payments, led by Canon Medical Systems USA, Inc. at 39.4% of the total. Reporting peaked in 2019 at $15,129 and has fallen 62.6% since, to $5,656 in 2025.

$56,129in general payments, 2019–2025

Across 246 payments — averaging $228.17 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

Canon Medical Systems USA, Inc.$22K
Boston Scientific$12K
Edwards Lifesciences$11K
Shockwave Medical, Inc$3K
Medtronic$2K
Philips North America LLC$1K
plus $5K from 22 others

$479,525in research payments, 2019–2025

Across 107 payments — averaging $4481.54 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

Edwards Lifesciences$415K
Abbott$52K
Boston Scientific$13K

$1,007,027in ownership & investment interests, 2019–2025

Across 14 payments — averaging $71,931 each. An ownership or investment interest held by the physician or an immediate family member.

Imperative Care, Inc$1M
Verge Medical, Inc.$1K

What the payments were for

Consulting fees$22,90041%
Speaking & faculty fees$9,20016%
Travel & lodging$8,95816%
Food & beverage$14,96227%
Entertainment$1090%

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
Canon Medical Systems USA, Inc.	32	$22,133
Boston Scientific	8	$12,233
Edwards Lifesciences	69	$10,742
Shockwave Medical, Inc	8	$2,600
Medtronic(2 entities)	24	$2,446
Philips North America LLC	16	$1,154
Abbott	12	$945
Abiomed	8	$916
W. L. Gore & Associates, Inc.	6	$690
Johnson & Johnson	31	$457
Recor Medical Inc	3	$308
ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)	2	$190
Inari Medical, Inc.	1	$161
Amgen	4	$160
Imperative Care, Inc	3	$145
Angiodynamics, Inc.	2	$138
Surmodics, Inc.	1	$134
Penumbra, Inc.	1	$125
Siemens Medical Solutions USA, Inc.	2	$115
Janssen Scientific Affairs, LLC	1	$93
Atricure, Inc.	1	$71
E.r. Squibb & Sons, L.L.C.	3	$45
Boehringer Ingelheim	2	$39
Astellas Pharma US Inc	2	$31
Terumo Medical Corporation	1	$17
Merck	1	$16
AstraZeneca	1	$15
Acutus Medical, Inc.	1	$9

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$56,129 in reported general payments places this provider in the 85th percentile of 171 interventional cardiology providers in Louisiana.

See all interventional cardiology providers in Louisiana →

Medicare billing

Part B allowed, 2024

$38,500

Medicare patients

Services billed

169

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

Drug	Claims	Cost to plans & patients
ClopidogrelClopidogrel Bisulfate	57	$604
Metoprolol Succinate	14	$275

Paid to pharmacies, not to this prescriber.

Other interventional cardiology in New Orleans

Rajan PatelNew Orleans$517K
James JenkinsNew Orleans$235K
Jose Tafur SotoNew Orleans$44K
Jose WileyNew Orleans$34K
Zach RozenbaumNew Orleans$18K
Aashish GuptaNew Orleans$18K
Craig WalkerHouma$5M
Denzil MoraesBaton Rouge$901K
Ankur LodhaLafayette$640K
Agostino IngraldiLafayette$315K

See the full list for Louisiana →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →